Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

Among patients with EGFR-mutated lung cancer after chemoradiotherapy, 65% of patients who received osimertinib were alive without progression at 2 years, as compared with 13% of those who received placebo.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology